FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Westover, David ^a   Ling, Xiang ^a,b   Lam, Hong ^a   Welch, Jacob ^a   Jin, Chunyang ^c   Gongora, Celine ^d   Del Rio, Maguy ^d   Wani, Mansukh ^c   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Canget BioTekpharma LLC   (United States)

^c RTI INTERNATIONAL   (United States)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

ABCG2; Anticancer drug; FL118; Human tumor animal models; Irinotecan; Resistance; Topoisomerase I

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; FIRTECAN; FL 118; IRINOTECAN; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 7-ETHYL-7-HYDROXY-10H-1,3-DIOXOLO(4,5-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-8,11(7H,12H)-DIONE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; INDOLIZINE DERIVATIVE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CANCER RESISTANCE; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE SILENCING; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; BENZODIOXOLES; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; INDOLIZINES; LUNG NEOPLASMS; MICE, SCID; NEOPLASM PROTEINS; TOPOISOMERASE INHIBITORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929145820     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0362-9     Document Type: Article

References (42)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789-802.
2. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:2237-44.
3. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.
4. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989;28:4629-38.
5. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 2001;41:53-77.
6. Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, et al. Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer. 2002;35:299-304.
7. Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, et al. New Topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer. 2011;10:64.
8. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665-70.
9. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007;110:138-47.
10. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer J International du cancer. 2004;109:848-54.
11. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol. 2000;60:831-7.
12. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001;288:827-32.
13. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003;63:5538-43.
14. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001;61:6635-9.
15. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004;65:1485-95.
16. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009;158:1153-64.
17. Li F. Anticancer drug FL118 is more than a survivin inhibitor: Where is the Achilles' heel of cancer? Am J Cancer Res. 2014;4:304-11.
18. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner. Shows Superior Antitumor Activity. PLoS One. 2012;7, e45571.
19. Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res. 2004;64:6679-83.
20. Knab AM, Fertala J, Bjornsti MA. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. J Biol Chem. 1995;270:6141-8.
21. Zhao J, Ling X, Cao S, Liu X, Wan S, Jiang T, et al. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Mol Pharm. 2014;11:457-67.
22. Ling X, Xu C, Fan C, Zhong K, Li F, Wang X. FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX. Cancer Research. 2014;74:7487-97.
23. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, et al. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer J International du cancer. 2004;108:146-51.
24. Allen JD, Van Loevezijn A, Lakhai JM, van der Valk M, Van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002;1:417-25.
25. Dallavalle S, Delsoldato T, Ferrari A, Merlini L, Penco S, Carenini N, et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem. 2000;43:3963-9.
26. Meco D, Di Francesco AM, Cusano G, Bucci F, Pierri F, Patriarca V, et al. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models. Cancer Chemother Pharmacol. 2012;70:811-22.
27. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 2003;63:3228-33.
28. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer J International du cancer. 2004;110:921-7.
29. Ling X, Li F. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res. 2013;5:139-54.
30. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010;9:677-8.
31. Sawada S, Nokata K, Furuta T, Yokokura T, Miyasaka T. Chemical modification of an antitumor alkaloid camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins. Chem Pharm Bull. 1991;39:2574-80.
32. Adams DJ, Da Silva MW, Flowers JL, Kohlhagen G, Pommier Y, Colvin OM, et al. Camptothecin analogs with enhanced activity against human breast cancer cells I. Correlation of potency with lipophilicity and persistence in the cleavage complex. Cancer Chemother Pharmacol. 2006;57:135-44.
33. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, et al. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007;13:1571-5.
34. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. J Biol Chem. 2004;279:15196-203.
35. Jo S, Vargyas M, Vasko-Szedlar J, Roux B, Im W. PBEQ-Solver for online visualization of electrostatic potential of biomolecules. Nucleic Acids Res. 2008;36:W270-5.
36. Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29:1859-65.
37. Huheey JE. The Electronegativity of Groups. J Phys Chem. 1965;69:3284-91.
38. Huheey JE. The Electronegativity of Multiply Bonded Groups. J Phys Chem. 1966;70:2086-92.
39. Inamoto N, Masuda S. Revised method for calculation of group electronegativities. Chem Lett. 1982;11:1003-6.
40. Wu H. Chemical Property Calculation through JavaScript and Applications in QSAR. Molecules. 1999;4:16-27.
41. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:23-30.
42. Schmittel A, Sebastian M, Fischer Von Weikersthal L, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011;22:1798-804.